FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940643432> ?p ?o ?g. }

• W2940643432 endingPage "2254" @default.
• W2940643432 startingPage "2247" @default.
• W2940643432 abstract "Abstract Purpose To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. Methods Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. Results At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. Conclusions Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration : NCT01997229, NCT02301624." @default.
• W2940643432 created "2019-05-03" @default.
• W2940643432 creator A5014242610 @default.
• W2940643432 creator A5029156957 @default.
• W2940643432 creator A5032850040 @default.
• W2940643432 creator A5035395158 @default.
• W2940643432 creator A5036542525 @default.
• W2940643432 creator A5065107885 @default.
• W2940643432 date "2019-03-23" @default.
• W2940643432 modified "2023-10-18" @default.
• W2940643432 title "Eculizumab improves fatigue in refractory generalized myasthenia gravis" @default.
• W2940643432 cites W1527112336 @default.
• W2940643432 cites W1899976422 @default.
• W2940643432 cites W1964566526 @default.
• W2940643432 cites W1983404333 @default.
• W2940643432 cites W1985265957 @default.
• W2940643432 cites W2004265876 @default.
• W2940643432 cites W2007508998 @default.
• W2940643432 cites W2011810065 @default.
• W2940643432 cites W2017640793 @default.
• W2940643432 cites W2042083490 @default.
• W2940643432 cites W2048953415 @default.
• W2940643432 cites W2066571580 @default.
• W2940643432 cites W2282042364 @default.
• W2940643432 cites W2497178382 @default.
• W2940643432 cites W2738300040 @default.
• W2940643432 cites W2766784006 @default.
• W2940643432 cites W2776638558 @default.
• W2940643432 cites W2790030937 @default.
• W2940643432 cites W2912901461 @default.
• W2940643432 doi "https://doi.org/10.1007/s11136-019-02148-2" @default.
• W2940643432 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6620379" @default.
• W2940643432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30905021" @default.
• W2940643432 hasPublicationYear "2019" @default.
• W2940643432 type Work @default.
• W2940643432 sameAs 2940643432 @default.
• W2940643432 citedByCount "27" @default.
• W2940643432 countsByYear W29406434322019 @default.
• W2940643432 countsByYear W29406434322020 @default.
• W2940643432 countsByYear W29406434322021 @default.
• W2940643432 countsByYear W29406434322022 @default.
• W2940643432 countsByYear W29406434322023 @default.
• W2940643432 crossrefType "journal-article" @default.
• W2940643432 hasAuthorship W2940643432A5014242610 @default.
• W2940643432 hasAuthorship W2940643432A5029156957 @default.
• W2940643432 hasAuthorship W2940643432A5032850040 @default.
• W2940643432 hasAuthorship W2940643432A5035395158 @default.
• W2940643432 hasAuthorship W2940643432A5036542525 @default.
• W2940643432 hasAuthorship W2940643432A5065107885 @default.
• W2940643432 hasBestOaLocation W29406434321 @default.
• W2940643432 hasConcept C111684460 @default.
• W2940643432 hasConcept C121332964 @default.
• W2940643432 hasConcept C126322002 @default.
• W2940643432 hasConcept C142424586 @default.
• W2940643432 hasConcept C142724271 @default.
• W2940643432 hasConcept C159110408 @default.
• W2940643432 hasConcept C159654299 @default.
• W2940643432 hasConcept C168563851 @default.
• W2940643432 hasConcept C1862650 @default.
• W2940643432 hasConcept C203014093 @default.
• W2940643432 hasConcept C204787440 @default.
• W2940643432 hasConcept C27081682 @default.
• W2940643432 hasConcept C2777991916 @default.
• W2940643432 hasConcept C2778105408 @default.
• W2940643432 hasConcept C2779951463 @default.
• W2940643432 hasConcept C42219234 @default.
• W2940643432 hasConcept C535046627 @default.
• W2940643432 hasConcept C71924100 @default.
• W2940643432 hasConcept C79544238 @default.
• W2940643432 hasConcept C87355193 @default.
• W2940643432 hasConceptScore W2940643432C111684460 @default.
• W2940643432 hasConceptScore W2940643432C121332964 @default.
• W2940643432 hasConceptScore W2940643432C126322002 @default.
• W2940643432 hasConceptScore W2940643432C142424586 @default.
• W2940643432 hasConceptScore W2940643432C142724271 @default.
• W2940643432 hasConceptScore W2940643432C159110408 @default.
• W2940643432 hasConceptScore W2940643432C159654299 @default.
• W2940643432 hasConceptScore W2940643432C168563851 @default.
• W2940643432 hasConceptScore W2940643432C1862650 @default.
• W2940643432 hasConceptScore W2940643432C203014093 @default.
• W2940643432 hasConceptScore W2940643432C204787440 @default.
• W2940643432 hasConceptScore W2940643432C27081682 @default.
• W2940643432 hasConceptScore W2940643432C2777991916 @default.
• W2940643432 hasConceptScore W2940643432C2778105408 @default.
• W2940643432 hasConceptScore W2940643432C2779951463 @default.
• W2940643432 hasConceptScore W2940643432C42219234 @default.
• W2940643432 hasConceptScore W2940643432C535046627 @default.
• W2940643432 hasConceptScore W2940643432C71924100 @default.
• W2940643432 hasConceptScore W2940643432C79544238 @default.
• W2940643432 hasConceptScore W2940643432C87355193 @default.
• W2940643432 hasFunder F4320309052 @default.
• W2940643432 hasIssue "8" @default.
• W2940643432 hasLocation W29406434321 @default.
• W2940643432 hasLocation W294064343210 @default.
• W2940643432 hasLocation W29406434322 @default.
• W2940643432 hasLocation W29406434323 @default.
• W2940643432 hasLocation W29406434324 @default.
• W2940643432 hasLocation W29406434325 @default.

• next